ASO Visual Abstract: Mutational Status is Associated with Higher Rate of Pathologic Complete Response After Neoadjuvant Chemotherapy in Hormone Receptor-Positive Breast Cancer

被引：0
|
作者：
Myers, Sara P. [1 ,2 ]
Sevilimedu, Varadan [3 ]
Barrio, Andrea V.
Tadros, Audree B. [1 ]
Mamtani, Anita [1 ]
Robson, Mark E. [4 ]
Morrow, Monica [1 ]
Lee, Minna K. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, Breast Serv, New York, NY 11553 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Med, Breast Med Serv, New York, NY USA
[3] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, Biostat Serv, New York, NY USA
[4] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
来源：
ANNALS OF SURGICAL ONCOLOGY | 2023年 / 30卷 / 13期
关键词：
D O I：
10.1245/s10434-023-14390-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：8469 / 8470
页数：2
相关论文
共 50 条
  • [41] ASO Visual Abstract: Prediction of Pathologic Complete Response in Breast Cancer Patients Comparing Magnetic Resonance Imaging with Ultrasound in the Neoadjuvant Setting
    Palshof, Frederik Knude
    Lanng, Charlotte
    Kroman, Niels
    Benian, Cemil
    Vejborg, Ilse
    Bak, Anne
    Talman, Maj-Lis
    Balslev, Eva
    Tvedskov, Tove Filtenborg
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (SUPPL 3) : 447 - 447
  • [42] ASO Visual Abstract: Neoadjuvant Chemotherapy and Endocrine Therapy for Older Patients with Estrogen Receptor Positive Breast Cancer—Comparison of Approaches
    Krislyn N. Miller
    Samantha M. Thomas
    Sydney M. Record
    Laura H. Rosenberger
    Maggie L. DiNome
    Gayle DiLalla
    Jeremy M. Force
    E. Shelley Hwang
    Jennifer K. Plichta
    Annals of Surgical Oncology, 2023, 30 : 6151 - 6151
  • [43] The impact of hormone receptor status on pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy with or without trastuzumab
    Peintinger, F.
    Buzdar, A.
    Kuerer, H.
    Gonzalez-Angulo, A.
    Hatzis, C.
    Pusztai, L.
    Esteva, F.
    Green, M.
    Hortobagyi, G.
    Symmans, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [44] Prognostic role of breast pathologic complete response after neoadjuvant chemotherapy in node-positive breast cancer patients
    Woo, J.
    Ryu, J. M.
    Lee, S. K.
    Yu, J.
    Lee, J. E.
    Kim, S. W.
    Nam, S. J.
    Chae, B. J.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S23 - S23
  • [45] High C-reactive protein is associated with the efficacy of neoadjuvant chemotherapy for hormone receptor-positive breast cancer
    Hu, Jiawei
    Luo, Zixuan
    Song, Junlong
    Kong, Deguang
    Li, Zhiyu
    Chen, Chuang
    Sun, Shengrong
    MEDICINE, 2024, 103 (48)
  • [46] Androgen receptor as predictive marker for pathologic complete response in breast cancer with neoadjuvant chemotherapy
    Lee, Eun-Gyeong
    Lee, Dong-Eun
    Han, Jai Hong
    Lee, Seeyoun
    Kang, Han-Sung
    Lee, Eun Sook
    Kwon, Youngmee
    Kim, Hyun Hee
    Chae, Hee Jung
    Sim, Sung Hoon
    Lee, Keun Seok
    Jung, So-Youn
    CANCER RESEARCH, 2022, 82 (04)
  • [47] Efficacy of chemotherapy after hormone therapy for hormone receptor-positive metastatic breast cancer
    Mori, Ryutaro
    Nagao, Yasuko
    SAGE OPEN MEDICINE, 2014, 2
  • [48] MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy
    Mette S. van Ramshorst
    Claudette E. Loo
    Emilie J. Groen
    Gonneke H. Winter-Warnars
    Jelle Wesseling
    Frederieke van Duijnhoven
    Marie-Jeanne T. Vrancken Peeters
    Gabe S. Sonke
    Breast Cancer Research and Treatment, 2017, 164 : 99 - 106
  • [49] MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy
    van Ramshorst, Mette S.
    Loo, Claudette E.
    Groen, Emilie J.
    Winter-Warnars, Gonneke H.
    Wesseling, Jelle
    van Duijnhoven, Frederieke
    Peeters, Marie-Jeanne T. Vrancken
    Sonke, Gabe S.
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 164 (01) : 99 - 106
  • [50] Are we overtreating hormone receptor-positive breast cancer with neoadjuvant chemotherapy? Correlating OncotypeDx® results with tumor response in patients undergoing neoadjuvant chemotherapy
    Kantor, Olga
    Kopkash, Katherine
    Pesce, Catherine
    Barrera, Ermilo
    Winchester, David
    Yao, Katharine
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 : 49 - 49
12345